Protonitazene is a benzimidazole derivative with potent opioid effects which has been sold over the internet as a designer drug since 2019, and has been identified in various European countries, as well as Canada, the US and Australia.

[1] It has been linked to numerous cases of drug overdose, and is a Schedule I drug in the US.

[2][3][4][5][6] It was developed by a Swiss pharmaceutical company in the 1950s as an alternative to morphine, but was never adopted due to severe side effects.

This analgesic-related article is a stub.

You can help Wikipedia by expanding it.